CYduct Diagnostics Recognized as April's "Innovator of the Month" by U.S. Senator Chris Murphy

WESTPORT, CT / ACCESSWIRE / May 4, 2023 / CYduct Diagnostics, Inc. (OTC PINK:CYDX) ("CYduct" or the "Company"), a company focused on developing life-enhancing breast healthcare products was recently recognized by U.S. Senator Chris Murphy (D-Conn.) as April's "Innovator of the Month."

CYduct is developing for commercialization the first personalized proteomic test for breast cancer risk assessment - B-FIRST™. The Company's product aims to accurately test for high-risk biomarkers that forecast the onset of breast cancer, helping women, physicians, and healthcare professionals make informed decisions about treatment options. The primary patient groups targeted by CYduct are known high-risk women and women with dense breast tissue, which is estimated to impact more than 45 million women in the U.S. alone.

CYduct's personalized risk assessment test has the potential to decrease the unacceptable high rates of false positives and false negatives in current risk assessment and screening tests, offering a more accurate and efficient way to diagnose breast cancer.

"Early detection and personalized care can be lifesaving for women impacted by breast cancer. The team at CYduct Diagnostics is doing important work to make that a reality. I'm proud to recognize their innovative approach and look forward to watching the company continue to grow in Connecticut," said Murphy.

CYduct CEO Dom Gatto stated, "We are thrilled to receive this recognition from Senator Murphy. Early detection is key to better outcomes for women with breast cancer. By developing accurate and personalized risk assessments, CYduct is paving the way for a more effective screening process and improved clinical decision-making. We are dedicated to improving the lives of women everywhere and believe that our work will make a significant difference in the fight against breast cancer."

CYduct's B-FIRST™ test is currently in development, and the Company is working closely with regulatory authorities to prepare for commercialization. With this recognition from Senator Murphy, CYduct is excited to continue its mission to empower women to take control of their Breast Health.

We encourage shareholders to visit our official corporate social media accounts as noted below for updates. Information on such platforms is not incorporated into this press release.

https://twitter.com/CYductDx
https://www.linkedin.com/company/cyductdx/
https://www.facebook.com/CYductDiagnostics

About CYduct Diagnostics, Inc.:

CYduct Diagnostics Inc. is a medical device company pursuing innovations within the women's healthcare market, primarily breast healthcare and wellness. CYduct is focused on breast health and wellness through new testing methods that prioritize clinical integrity and patient privacy and convenience. The Company's history is rooted in providing quality medical products to healthcare markets across the United States. For more than 30 years, from medical schools to hospitals, physicians have relied on the Company to develop medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions.

Additional information on its line of products will be available on the Company's website at: CYductDX.com.

FORWARD-LOOKING STATEMENTS; ADDITIONAL INFORMATION

This press release includes certain information that may constitute forward-looking statements. Forward-looking statements are typically identified by terminology such as "could," "may," "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "proposed," "planned," "potential" and similar expressions, or are those, which, by their nature, refer to future events. All statements, other than statements of historical fact, included herein, including statements about CYduct's beliefs and expectations, are forward-looking statements. Forward-looking information is necessarily based upon a number of assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information. Although CYduct believes that such statements are reasonable, it can give no assurance that such forward-looking information will prove to be accurate. CYduct cautions investors that any forward-looking statements by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward-looking statements as a result of various factors. Accordingly, due to the risks, uncertainties and assumptions inherent in forward-looking information, readers and prospective investors in the Company's securities should not place undue reliance on forward-looking information. All forward-looking information contained in this press release is given as of the date hereof and is based upon the opinions and estimates of management and information available to management as at the date hereof and is subject to change. The Company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the Company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The Company assumes no obligation to revise or update forward-looking information to reflect new circumstances, whether as a result of new information, future events or otherwise, except as required by law.

CONTACT:

CYduct Diagnostics, Inc.
Investor Relations +1-888-545-9112

SOURCE: CYduct Diagnostics, Inc